Carbon monoxide screening in ED patients with headache Injury, Occupational Diseases, Poisoning
Conditions
Interventions
The data collected in this study will be pseudoanonymised and all participants will be assigned a unique identification (ID) number. The clinical research team at the hospital will have access to a da
Sponsors
St George’s University Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. ‘Walk in’ adult patients = 18yrs 2. Presenting with symptoms of headache (either as the main symptom or as part of a cluster of symptoms). This includes patients with suspected CO exposure. 3. Willing and able to give informed consent for participation in the study 4. Willing and able to return the study CO monitor within 5 days of the end of the CO monitoring period 5. Likely to be discharged from the ED
Exclusion criteria
Exclusion criteria: 1. Children under the age of 18 years 2. Headache precipitated by another condition, e.g. head trauma or stroke 3. Clinical condition warranting immediate or urgent medical assessment 4. Patients lacking the capacity to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of the methodology will be measured by assessing the number of eligible versus enrolled patients, the data completeness from participants and the withdrawal/non-complete rates collected from study records throughout the trial and at the study endpoint | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The proportion of patients presenting to Emergency Departments with simple headaches who have been exposed to carbon monoxide (percentage), measured using data collected from study records at baseline. 2. The agreement between CO levels measured through blood tests, CO-oximetry, and home monitoring, and their correlation (comparative statistics) with screening questionnaire responses at baseline and patient self-reported symptoms measured using a questionnaire involving headache characteristics and CO poisoning symptoms during the 7-day monitoring period, and at days 14 and 42 post-discharge. 3. Prevalence and symptoms during different seasons will be used to characterise levels and temporal variations in CO exposure in homes. This will be measured using environmental CO data collected during the 7-day monitoring period, with a comparison of positive results across different times of year. 4. Recruitment, retention, data completeness, and participant adherence to study procedures (percentage) measured using comparison of the number of participants who are approached (screening), the number of participants who enrol into the study (baseline) and the number of patients who complete all study procedures (day 42 follow-up). | — |
Countries
England, United Kingdom
Contacts
Public ContactKathryn;Richard Willis;Atkinson
;
Outcome results
None listed